Cargando…
P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY.
Autores principales: | Yu, Dan, Cheng, Hui, Guo, Jingming, Jiang, Rui, Zhang, Youshan, Wan, Chucheng, Qin, Jun, Yuan, Guolin, Chen, Shiming, Yang, Zhuangzhi, Hu, Junbin, Zhang, Yicheng, LI, Weiming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429722/ http://dx.doi.org/10.1097/01.HS9.0000969568.85601.05 |
Ejemplares similares
-
COVID-19 in persons with chronic myeloid leukaemia
por: Li, Weiming, et al.
Publicado: (2020) -
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
por: Schaars, CF, et al.
Publicado: (2006) -
Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison
por: Valdes, Audrey, et al.
Publicado: (2018) -
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group
por: Iriyama, Noriyoshi, et al.
Publicado: (2017) -
Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)